Paratek Pharmaceuticals' Nuzyra (omadacycline) Receives FDA Approval for Community-Acquired Bacterial Pneumonia (CABP) and Acute Skin and Skin Structure Infections (ABSSSI) in Adults
Shots:
- The approval is based on multiple trial study assessing Nuzyra and resulted in safe- efficacious and well tolerated results
- Nuzyra (omadacycline) is a qd IV PO tetracycline class antibacterial drug indicated to treat CABP and ABSSSI
- Post marketing approval- Paratek’s plans to evaluate Nuzyra for the treatment of CABP and pediatrics- with its expected marketing in Q1’19
Ref: Paratek Pharmaceuticals | Image: Glassdoor
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
